Bicara Therapeutics (NASDAQ:BCAX) Releases Quarterly Earnings Results, Hits Estimates

Bicara Therapeutics (NASDAQ:BCAX) posted its earnings results on Tuesday. The company reported ($0.82) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.82), Zacks reports.

Here are the key takeaways from Bicara Therapeutics’ conference call:

• Management highlighted three-year follow-up data for FICERA in HPV-negative head and neck cancer, saying approximately one in three patients remained alive at three years—nearly double retrospective standard-of-care estimates—while maintaining a consistent safety profile.
• The pivotal FORTIFI-HN01 study remains on track for substantial enrollment by year-end, with more than 200 sites active and a planned interim analysis in mid-2027 that could support a potential accelerated approval.
• Bicara initiated the FORTIFI-FLEX study to evaluate loading and every-three-week maintenance dosing, aiming to have data available by a potential U.S. approval and support inclusion of a more convenient regimen in the product label.
• The company reported approximately $497 million in cash and marketable securities at quarter-end, providing projected runway into the first half of 2029, while warning that operating expenses will rise as pivotal-trial, manufacturing, medical-affairs, and commercial-launch investments increase.
• Leadership transitions will take effect as Ryan Cohlhepp becomes CEO and Claire Mazumdar moves to vice chair and strategic advisor; Bicara also announced new finance, operations, business, and legal leadership intended to support potential commercialization.

Bicara Therapeutics Stock Performance

Shares of Bicara Therapeutics stock traded down $2.56 during trading hours on Tuesday, reaching $25.17. The company’s stock had a trading volume of 650,164 shares, compared to its average volume of 599,421. The stock’s fifty day simple moving average is $25.82 and its two-hundred day simple moving average is $21.64. The company has a market capitalization of $1.65 billion, a P/E ratio of -9.04 and a beta of -0.75. Bicara Therapeutics has a one year low of $9.67 and a one year high of $30.99.

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 28,214 shares of the business’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $28.98, for a total transaction of $817,641.72. Following the completion of the sale, the chief operating officer directly owned 182,177 shares of the company’s stock, valued at approximately $5,279,489.46. The trade was a 13.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 28,000 shares of Bicara Therapeutics stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $28.85, for a total value of $807,800.00. Following the transaction, the chief financial officer directly owned 129,855 shares in the company, valued at approximately $3,746,316.75. The trade was a 17.74% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 88,450 shares of company stock valued at $2,366,675. 13.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Legal & General Group Plc increased its stake in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares during the last quarter. Larson Financial Group LLC increased its position in shares of Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after purchasing an additional 3,595 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after purchasing an additional 3,866 shares during the last quarter. New York State Common Retirement Fund raised its stake in shares of Bicara Therapeutics by 87.5% during the 4th quarter. New York State Common Retirement Fund now owns 7,500 shares of the company’s stock worth $126,000 after purchasing an additional 3,500 shares during the period. Finally, Creative Planning purchased a new position in shares of Bicara Therapeutics in the 3rd quarter worth about $159,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BCAX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Monday, July 6th. Morgan Stanley upped their price objective on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, May 24th. Finally, The Goldman Sachs Group increased their price objective on Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $30.27.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.